GlassScriptPhysician profile
Breana Schroeder
NPI 1912789678
$3,881.18
in general payments reported to CMS, 2019-2025
27 companies · $2,445 in 2025
The $2,445 reported for 2025 was more than what 97% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $60.99 · 2024: $1,375 · 2025: $2,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,816 · Education: $65.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,815.76 |
| Education | $65.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $753.45 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $615.75 | 2023-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $519.60 | 2023-2025 | Entyvio, Eohilia |
| Lucid Diagnostics INC. | $327.90 | 2024-2025 | |
| Qol Medical, LLC | $210.11 | 2024-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $184.46 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $162.65 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $161.88 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $124.80 | 2024-2025 | Stelara, Tremfya, Simponi Aria |
| Ipsen Biopharmaceuticals, INC | $116.32 | 2024-2025 | Iqirvo |
| Organon LLC | $98.69 | 2024-2025 | Hadlima, Renflexis, Nexplanon |
| Regeneron Healthcare Solutions, INC. | $94.05 | 2024-2025 | Dupixent |
| Celltrion USA INC. | $92.72 | 2024-2025 | Vegzelma, Zymfentra |
| Madrigal Pharmaceuticals | $92.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $57.58 | 2024 | Dificid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $44.94 | 2024-2025 | |
| Sandoz INC. | $35.88 | 2024-2025 | Hyrimoz |
| Shield Therapeutics INC | $31.60 | 2024 | |
| Aimmune Therapeutics, INC. | $28.79 | 2025 | Vowst |
| Pfizer INC. | $18.52 | 2025 | |
| Inspire Medical Systems, INC. | $17.88 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.32 | 2024 | Cyltezo |
| Evoke Pharma, INC. | $16.07 | 2024 | |
| Medtronic, INC. | $15.85 | 2024 | Gi Genius |
| Braintree Laboratories, INC. | $14.43 | 2025 | Sutab, Suflave |
| Astrazeneca Pharmaceuticals LP | $13.65 | 2025 | |
| Ironwood Pharmaceuticals, INC | $13.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Breana Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.